Target Name: MIR182
NCBI ID: G406958
Review Report on MIR182 Target / Biomarker Content of Review Report on MIR182 Target / Biomarker
MIR182
Other Name(s): hsa-mir-182 | hsa-miR-182-5p | miRNA182 | mir-182 | MicroRNA 182 | hsa-miR-182-3p | MIRN182 | microRNA 182

MIR182: A Potential Drug Target and Biomarker for Multiple Sclerosis

Multiple sclerosis (MS) is a chronic and debilitating autoimmune disorder that affects millions of people worldwide. It is characterized by the immune system attacking the central nervous system, leading to a range of symptoms such as muscle weakness, vision problems, and balance issues. There is currently no cure for MS, and numerous drug treatments have only managed to slow down the progression of the disease. As such, identifying potential drug targets and biomarkers for MS is a promising approach to developing new treatments. In this article, we will focus on MIR182, a gene that has shown promise in clinical trials for treating MS.

MIR182 is a non-coding RNA molecule that is expressed in various tissues throughout the body. It is a part of a family of genes called miRNA (microRNA) genes, which are known for their ability to regulate gene expression. MIR182 has been shown to play a role in the development and progression of MS, as well as other diseases.

One of the key functions of MIR182 is its ability to regulate the activity of immune cells, particularly T cells. T cells are a crucial part of the immune system, and play a major role in attacking the central nervous system in MS. MIR182 has been shown to reduce the activity of T cells, which may help to reduce the immune response that contributes to the development of MS.

In addition to its role in immune regulation, MIR182 has also been shown to play a role in the development of neurodegeneration. Studies have shown that MIR182 is expressed in the brains of people with MS, and that it is involved in the development of neurofibrillary tangles and other hallmark signs of neurodegeneration. This suggests that MIR182 may be a potential drug target for MS.

Despite the potential benefits of MIR182 as a drug target, there are also several concerns about its safety and effectiveness. For example, some studies have suggested that MIR182 may be too safe to be used in humans, as it has not been shown to cause significant side effects when administered to this species. Additionally, the lack of a clear mechanism of action for MIR182 may make it difficult to predict how it will interact with other molecules in the body.

Despite these challenges, MIR182 remains a promising drug target for MS. The development of new treatments for MS is a critical step in understanding and managing this disease. As such, further research is needed to fully understand the potential of MIR182 as a drug target and biomarker for MS.

In conclusion, MIR182 is a non-coding RNA molecule that has shown promise in clinical trials for treating MS. Its ability to regulate the activity of immune cells and its involvement in the development of neurodegeneration make it a potential drug target for MS. While further research is needed to fully understand its potential, MIR182 is a promising biomarker and drug target for MS.

Protein Name: MicroRNA 182

The "MIR182 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR182 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR1825 | MIR1827 | MIR183 | MIR184 | MIR185 | MIR186 | MIR187 | MIR188 | MIR18A | MIR18B | MIR1908 | MIR1909 | MIR190A | MIR190B | MIR191 | MIR1910 | MIR1911 | MIR1912 | MIR1913 | MIR1914 | MIR1915 | MIR1915HG | MIR192 | MIR193A | MIR193B | MIR193BHG | MIR194-1 | MIR194-2 | MIR194-2HG | MIR195 | MIR196A1 | MIR196A2 | MIR196B | MIR197 | MIR1972-1 | MIR1972-2 | MIR1973 | MIR1976 | MIR198 | MIR199A1 | MIR199A2 | MIR199B | MIR19A | MIR19B1 | MIR19B2 | MIR200A | MIR200B | MIR200C | MIR200CHG | MIR202 | MIR202HG | MIR203A | MIR203B | MIR204 | MIR205 | MIR2052 | MIR2052HG | MIR2053 | MIR2054 | MIR205HG | MIR206 | MIR208A | MIR208B | MIR20A | MIR20B | MIR21 | MIR210 | MIR210HG | MIR211 | MIR2110 | MIR2113 | MIR2114 | MIR2115 | MIR2116 | MIR2117 | MIR212 | MIR214 | MIR215 | MIR216A | MIR216B | MIR217 | MIR217HG | MIR218-1 | MIR218-2 | MIR219A1 | MIR219A2 | MIR219B | MIR22 | MIR221 | MIR222 | MIR223 | MIR224 | MIR2276 | MIR2277 | MIR2278 | MIR22HG | MIR2355 | MIR2392 | MIR23A | MIR23AHG